Table 2. Unadjusted crude outcomes for patients with microbiologically confirmed community-acquired COVID-19 (19 February – 22 July 2020) or influenza A/B infections (26 October 2018 – 26 March 2020), Switzerland (n = 4,224).

	SARS-CoV-2 (n = 2,843)		Influenza A/B (n = 1,381)		p value
	n	%	n	%	p value
In-hospital deaths	363	12.8	61	4.4	< 0.001
Admission to the ICU	483	19.4	129	9.8	< 0.001
Invasive ventilation	394	13.9	66	4.8	< 0.001
Respiratory complications	2,082	93.6^a	744	83.9^b	< 0.001
Cardiac diseases	556	25.0^a	212	23.9^b	0.291
Neurologic impairment	394	17.7^a	82	9.2^b	< 0.001
Renal impairment	601	27.0^a	149	16.8^b	< 0.001
Length of hospital stay, median (IQR)	8 (5–16)		7 (4–13)		< 0.001
Any antibiotic treatment	1,539	61.7^c	862	65.7^d	< 0.001

COVID-19: coronavirus disease; ICU: intensive care unit; IQR: interquartile range; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

^a Missing values n (%): 618 (22%) as reporting of these complications was not mandatory and omitted by some centres.

^b Missing values n (%): 494 (36%) as reporting of these complications was not mandatory and omitted by some centres.

^c Missing values n (%): 349 (12) as reporting of these complications was not mandatory and omitted by some centres.

^d Missing values n (%): 69 (5) as reporting of these complications was not mandatory and omitted by some centres.